Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by Target PharmaSolutions, Inc.
Sponsor:
Information provided by (Responsible Party):
Target PharmaSolutions, Inc.
ClinicalTrials.gov Identifier:
NCT02815891
First received: June 23, 2016
Last updated: March 27, 2017
Last verified: March 2017
  Purpose
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFL or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients with NAFL or NASH within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Condition
Nonalcoholic Fatty Liver
Nonalcoholic Steatohepatitis

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Other
Target Follow-Up Duration: 5 Years
Official Title: A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)

Resource links provided by NLM:


Further study details as provided by Target PharmaSolutions, Inc.:

Primary Outcome Measures:
  • Establish an understanding of the current natural history of NASH at academic and community medical centers [ Time Frame: up to 5 years ]
    A detailed analysis of demographics, concurrent medications, metabolic and cardiovascular co-morbidities, staging of liver disease, and outcomes for patients with NASH managed in diverse clinical settings will serve as an important comparator for subsequent interventions that alter the treatment paradigm for this disease.

  • Evaluate NASH treatment regimens being used in clinical practice [ Time Frame: up to 5 years ]
    Currently, there are no FDA approved therapies for NASH, however clinicians may use a variety of interventions including diet and exercise programs, vitamin E, bariatric surgery or other unapproved uses of some cholesterol, lipid lowering, anti-diabetic and anti-inflammatory medications as well as alternative medications. TARGET-NASH will monitor the safety and effectiveness of the various treatment choices in enrolled patients.

  • Examine populations underrepresented in phase II-III clinical trials [ Time Frame: up to 5 years ]
    Patients with cirrhosis, age > 70, patients who consume moderate amounts of alcohol and patients with multiple comorbidities such as severe depression, chronic fatigue, fibromyalgia, type 2 diabetes, inflammatory bowel disease, or cardiovascular disease.

  • Evaluate optimal duration and combination of NASH therapies to achieve clinical response and clinical remission [ Time Frame: up to 5 years ]
    In addition to diet and exercise, type, dose and duration of therapy of each NASH treatment (both current unapproved therapies and future FDA approved drugs) will be closely followed, with a goal to monitor treatment paradigms and various combination regimens for clinical response and clinical remission.

  • Examine liver histology [ Time Frame: up to 5 years ]
  • Estimate adverse event frequency and severity and describe management practices [ Time Frame: up to 5 years ]
    NASH can often be an asymptomatic disease in the setting of other disease-related comorbidities such as diabetes and cardiovascular disease. Once NASH progresses to cirrhosis, these patients can suffer the attendant complications of decompensated liver disease including debilitating fatigue, muscle wasting, ascites, bleeding, encephalopathy, hepatocellular carcinoma, and death. NASH therapies may increase the frequency and severity of certain adverse events, such as edema (pioglitazone), some cancers (vitamin E), and new agents or combinations of agents may have their own unique adverse event profiles and varying needs for management plans (e.g., pruritus and dyslipidemia).

  • Evaluate the impact of NASH therapies on medical co-morbidities [ Time Frame: up to 5 years ]

Biospecimen Retention:   Samples With DNA
Patients enrolled in TARGET-NASH will be invited to participate in the Biorepository Specimen Bank (BSB). Blood samples for biomarker and DNA assays will be collected on a voluntary basis and participation in this project will not affect participation in the main study. These samples will be shipped to a central repository for storage to use in future studies. Samples stored at the biorepository will be identified only with the patient's unique study ID number and the date that the sample was obtained. This link between the patient's study ID number and their name will be available only at the site where the samples were obtained.

Estimated Enrollment: 15000
Study Start Date: July 2016
Estimated Study Completion Date: July 2021
Estimated Primary Completion Date: July 2021 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults and children with NAFL or NASH who are being seen specifically to address this disease process
Criteria

Inclusion Criteria:

1. Adults and children (age 6 or older) being managed or treated for NAFL or NASH

Exclusion Criteria:

  1. Inability to provide written informed assent/consent
  2. Simultaneous enrollment in another registry, study, or clinical trial where NASH treatment outcomes are reported, except where approved or conducted as an adjunct project of TARGET-NASH
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02815891

Contacts
Contact: Laura Malahias lmalahias@targetpharmasolutions.com

  Show 32 Study Locations
Sponsors and Collaborators
Target PharmaSolutions, Inc.
  More Information

Responsible Party: Target PharmaSolutions, Inc.
ClinicalTrials.gov Identifier: NCT02815891     History of Changes
Other Study ID Numbers: TARGET-NASH
Study First Received: June 23, 2016
Last Updated: March 27, 2017
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on April 28, 2017